Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Orbassano – page 17

215 clinical trials in Orbassano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Orbassano at a glance
215
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

215 trials in Orbassano

Open in trial search

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Thymoma+1

Not recruiting

Study on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on MK-7684A and Docetaxel for Treating Metastatic Non-Small Cell Lung Cancer in Patients After Platinum Chemotherapy and Immunotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Thalassaemia alpha

Not recruiting

Study on Luspatercept for Treating Anemia in Adults and Adolescents with Alpha-Thalassemia

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Orbassano

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer and mesothelioma treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Non-Small Cell Lung Cancer (NSCLC) Studies
  • Pleural Mesothelioma Treatments
  • Renal Cell Carcinoma Research

Multiple trials evaluating immunotherapy approaches and targeted molecular treatments for advanced stages of cancer.

02 Hematological Disorders

Research initiatives investigating treatments for blood disorders and related conditions, with particular focus on innovative therapies.

  • Sickle Cell Disease Management
  • Acute Myeloid Leukemia Treatments
  • Lymphoblastic Leukemia Studies

Studies examining new therapeutic approaches for blood disorders and their complications.

03 Cardiovascular Research

Clinical investigations focusing on heart failure prevention and innovative cardiovascular treatments.

  • Heart Failure Prevention Studies
  • Cardiovascular Risk Management
  • Novel Drug Combinations

Trials evaluating new therapeutic approaches for reducing cardiovascular events and improving patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.